ArticleGalen medical journal2024
Gallic Acid Alleviates Injury of Intestine Induced by Escherichia Coli: Protective Role of Metalloproteinase and Antioxidants on Small Intestine In-vivo.
Article in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEscherichia coli (E. coli) is a common pathogen that can cause significant morbidity and mortality in hospitalized patients. The aim of this study was to investigate the effects of gallic acid (GA) on a mice infected with of E. coli enteritis and evaluate the serum levels of interleukin-6 (IL-6) and matrix metalloproteinase (MMP)-9, as well as any histopathological changes before and after exposure. MATERIALS AND
methodsForty Swiss male mice were divided into four groups: Group I (negative control), Group II (received oral GA, 80 mg/kg/b.wt), Group III (orally inoculated with E. coli, 1×107 CFU, for four days), and Group IV (received oral GA, 80 mg/kg/b.wt, for 10 days after E. coli inoculation). Serum was collected to assess IL-6 and MMP-9 levels. Intestinal samples were examined for antioxidant parameters, including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase. Histopathology and immunohistochemistry were performed.
resultsGroup III exhibited significantly higher IL-6 and MMP-9 levels compared to the other groups (P0.001). Antioxidant activity in the intestine, measured by SOD and GSH-Px, was lower in Group III compared to Group I. Conversely, Group IV showed significant improvements in biochemical, histopathological, and immunohistochemical outcomes, alongside reduced intestinal damage caused by E. coli.
conclusionThis study demonstrates that E. coli infection in mice increases IL-6 and MMP-9 levels while decreasing intestinal antioxidants. Concurrent administration of GA significantly improves outcomes, suggesting its potential as a therapeutic remedy for E. coli-induced intestinal damage. Furthers research is imperative to determine the underlying pathways by which GA exerts its beneficial outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.